Kiniksa Pharmaceuticals International, plc (KNSA)

Market Cap	3.62B +119.0%
Revenue (ttm)	677.56M +60.1%
Net Income	59.01M
EPS	0.75
Shares Out	76.54M
PE Ratio	63.07
Forward PE	39.42
Dividend	n/a
Ex-Dividend Date	n/a

Volume	350,975
Open	47.35
Previous Close	47.08
Day's Range	46.60 - 48.46
52-Week Range	19.41 - 50.03
Beta	0.06
Analysts	Strong Buy
Price Target	55.29 (+16.89%)
Earnings Date	Apr 28, 2026

About KNSA

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericard...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: May 24, 2018
• Employees: 366
• Stock Exchange: NASDAQ
• Ticker Symbol: KNSA
• Website: https://www.kiniksa.com

Analyst Summary

According to 7 analysts, the average rating for KNSA stock is "Strong Buy." The 12-month stock price target is $55.29, which is an increase of 16.89% from the latest price.

Price Target

$55.29

(16.89% upside)

Analyst Consensus: Strong Buy